EDAP TMS is a pioneer and a market leader in Extracorporeal Shockwave Lithotripsy (ESWL) with the Sonolith® range of devices. With Ablatherm® HIFU and its recently introduced Focal One®, EDAP TMS is the the leader in High Intensity Focused Ultrasound (HIFU) for the treatment of Prostate Cancer. Both technologies are based on ultrasound waves but their markets and contexts are distinct, and they therefore require specific marketing strategies.
The Company’s business strategy is to capitalize on its expertise in therapeutic ultrasound and its position in urology to achieve long-term growth as a leader in the development, production, marketing and distribution of minimally-invasive medical devices for urological and other indications, primarily using HIFU and shock wave technologies.
Focal HIFU for Prostate Cancer
Focal treatment strategy for Prostate
Cancer (PCa) is playing a growing role in today’s surgical practice. By combining the latest imaging and treatment technologies, Focal One® brings the answer to current requirements for ideal focal therapy: accurate and MR-fused imaging,
non-invasive approach, precise and efficient therapeutic HIFU energy and treatment validation imaging with post-treatment MRI
Non-invasive treatment for prostate cancer
The Ablatherm® HIFU device has been developed since 1993 for the radical treatment of localized prostate cancer. It is suitable for men who are at risk for surgery due to their age or other associated illnesses, or who may not want to undergo surgery. It may also be suitable for men with cancer have recurrence following radiotherapy.